← FDA DRUG APPROVALS

FDA ANDA · ANDA078052

FOSPHENYTOIN

fosphenytoin sodium

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA078052
TYPE
ANDA
ORIGINAL APPROVAL
2007-08-06
LATEST ACTION
2020-08-28
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

FOSPHENYTOIN SODIUMPrescription
FOSPHENYTOIN SODIUM EQ 50MG PHENYTOIN NA/ML · INJECTABLE · INJECTION

Approval history

2020-08-28Labeling · Supplement 15 · standardAP
2019-11-04Labeling · Supplement 12 · standardAP
2019-11-04Labeling · Supplement 10 · standardAP
2019-11-04Labeling · Supplement 8 · standardAP
2019-11-04Labeling · Supplement 11 · standardAP
2016-05-16Labeling · Supplement 7 · standardAP
2016-01-30Labeling · Supplement 5 · standardAP
2016-01-30Labeling · Supplement 3 · standardAP
2016-01-30Labeling · Supplement 6 · standardAP
2016-01-30Labeling · Supplement 4 · standardAP
2013-08-22Labeling · Supplement 2 · standardAP
2007-08-06OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →